Guided by Scientific Rigor, Advancing Life's Potential

AI-empowered, dual-engine driven by LBP and small molecules: developing breakthrough therapies and continuously contributing innovative drugs to the industry. 

 
 
 
 

View Details →

R&D Pipelines

Lishan Biotech specializes in the research and development of innovative drugs, creating sustainable value for the enhancement of human life quality. Its core pipeline includes Small Molecule (SM) drugs with globally leading mechanisms of action, as well as Live Biotherapeutic Products (LBP), known as the "third-generation therapy".

View Details →

Swarming Technology

Swarming is a bacterial motility phenotype characterized by collective cooperative migration behavior, accompanied by adaptive changes in bacterial morphology and metabolic pathways. In the environment of intestinal inflammation, high concentrations of reactive oxygen species, rough interfaces formed by mucosal damage, and high iron ion concentrations caused by bleeding collectively induce the enrichment of facultative anaerobic Swarming bacteria, making them potential biomarkers of intestinal inflammation. Experiments have shown that compared to Swarming phenotype knockout strains, natural Swarming strains are more effective in alleviating intestinal inflammation. At present, Swarming technology has been applied in the treatment of Crohn's disease in the LS-LBP-001 pipeline.

View Details →

IMicAP Microbial Platform

Lishan Biotech and the Institute of Intelligent Medicine at Fudan University jointly established the "Intelligent Microbiome School Enterprise Joint Laboratory" in 2023. With the knowledge support of the precision medicine knowledge base of the Institute of Intelligent Medicine and the data support of 18 affiliated hospitals, combined with the research results of the company's early participation in the "Human Microbiome Program", they independently developed the Intelligent Microbial Application Platform (IMicAP), obtained national authorized invention patents and international PCT protection, and are committed to becoming a leader in the global "AI+Microbiology" sub field.

View Details →

Login to IMicAP →

Research Articles

Innovation is the driving force behind Lishan Biotech's continuous progress.

More Articles →

Bacterial swarmers enriched during intestinal stress ameliorate damage

Gastroenterology

2021

JUL

Confinement discerns swarmers from planktonic bacteria                                               

eLife

2021

APR

Identifying determinants of bacterial fitness in a model of human gut microbial succession

PNAS

2020

JAN

Multimodal reasoning based on knowledge graph embedding for specific diseases

Bioinformatics

2022

FEB

News & Events

Lishan Biotech always walks alongside those who share the same vision.

More Events →

More News →

26

2026-01

Company Events

Looking forward to a promising future, we march together on the journey...

As the new chapter unfolded, with the dawn of the New Year illuminating the serene and vibrant landscape of...

More Events →

  • 2026-04-27
    April 24, 2026 – Dr. William Chen, Chairman of Lishan Biotech, has added another honor to his name. At the 2025 Pudong New Area “Pearl Cup” Entrepreneurship Competition, Dr. Chen and his team won the “Most Promising Overseas Returnee Entrepreneurship Team Award” for their project, the “World-Class Live Biotherapeutic Product (LBP) Platform for Gut Microbiome.” The competition was hosted by Pudong Venture Capital Group and guided by the Pudong New Area Talent Work Bureau. It aimed to attract overseas and domestic tech talent entrepreneurship projects through a model of “competition-based evaluation and investment linkage.” Focusing on three leading industries—integrated circuits, biomedicine, and artificial intelligence—the competition drew numerous projects from home and...
  • 2026-03-23
    Innovation Drives the Future——Though the Journey is Long, Perseverance Leads to Success Recently, Shanghai Lishan Biotech Co., Ltd. has received exciting news—it has officially been recognized as a National High-Tech Enterprise and has been awarded the "High-Tech Enterprise Certificate" jointly issued by the Shanghai Science and Technology Commission, the Shanghai Municipal Finance Bureau, and the Shanghai Municipal Office of the State Administration of Taxation. This recognition marks that Lishan Biotech has met the national standards for high-tech enterprises in areas such as innovative drug development, technological innovation, and achievement commercialization, serving as a strong endorsement of the company's sustained innovation capabilities and scientific research strength.   AI-Empowered: The Innovation Engine f...
  • 2026-02-27
    At the beginning of the Year of the Horse, on the afternoon of February 26th, the "New Overseas Chinese Innovation and Entrepreneurship in Shanghai" activity, organized by the Shanghai Federation of Returned Overseas Chinese to visit overseas Chinese enterprises and facilitate practical work, entered Zhangjiang Pharma Valley and held a thematic seminar at Lishan Biotech. A delegation comprising Qi Quansheng, Party Secretary and Chairman of the Shanghai Federation of Returned Overseas Chinese; Guo Qing, Vice Chairman of the Municipal Federation and concurrently Party Secretary and Chairman of the Pudong New Area Federation; and Cheng Dong, Chairman of the Zhangjiang Science City Federation, among others, visited the company. Li Zhi, Deputy Director of Corporate Communications at Junshi Biosciences, and Shang Jing, Executive D...
  • 2026-02-05
    BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results   Rehovot, Israel and Shanghai, China – February 4, 2026 – Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biotech Co., Ltd. ("Lishan Biotech"), a China-based clinical-stage biotechnology company focused on innovative therapies in the fields of immunity and inflammation, today announced that Biomica Ltd. ("Biomica"), Evogene’s subsidiary and Lishan Biotech entered into an exclusive worldwide licensing agreement for BMC128 (designated as LS-LBP-002 by Lishan Biotech), a first-in-class microbiom...
  • 2025-12-15
    In order to highlight the innovation and vitality of Zhangjiang's life science industry, the WeChat official account of "Zhangjiang Pharmaceutical Valley" launched the column of "New Talents of Pharmaceutical Valley", and invited new enterprises of Zhangjiang Pharmaceutical Valley to have in-depth dialogue and decode innovation. In this issue, we will have a conversation with Dr. William Chen, Chairman of Shanghai Lishan Biopharmaceutical Co., Ltd. (hereinafter referred to as "Lishan Biotech"), to learn how the company has embarked on a path of cross-border integration and innovation. William Chen, Chairman of Lishan Biotechnology   At the National Finals of the 3rd National Postdoctoral Innovation and Entrepreneurship Competition, which concluded in October 2025, Dr.William Chen, Chairman of Lishan Biotech, led the "Inte...
  • 2025-10-31
    The final of the 3rd National Postdoctoral Innovation and Entrepreneurship Competition, co hosted by the Ministry of Human Resources and Social Security and the People's Government of Fujian Province, was successfully concluded in Quanzhou, Fujian Province from October 26-28, 2025. After fierce competition and rigorous evaluation, Dr. William Chen, Chairman of Lishan Biotechnology, led the project of "Intestinal Microbial Live Biopharmaceuticals for Crohn's Disease Treatment", which stood out among many excellent participating projects in the biopharmaceutical field and won the silver medal in this competition. This innovation competition has received high attention, with more projects and participants than the first and second editions. It gathers seven major tracks including new generation information technology and artificial intelligence, high-end e...
  • 2025-10-16
    On October 16, 2025, Shanghai Lishan Biopharmaceutical Co., Ltd. officially obtained the GB/T 19001-2016/ISO 9001:2015 quality management system certification issued by the international authoritative certification body BCC.     The Road to Building the ISO9001 Quality Management System in Lishan Biotech ISO9001 is the globally recognized and most mature quality management system framework, published by the International Organization for Standardization (ISO) and widely adopted by various organizations around the world. This system is based on "quality" and rooted in "quality", committed to continuously improving product and service levels through systematic and standardized management. Obtaining ISO9001 certification is not only a powerful manifestation of a company's pursuit of excellence, but also an important cornerstone for achievin...

Company News

Regularly update company updates, follow us for quick access to the latest company news.

More News →

  • toolbar